Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MC4R | P32245 | 3/20 | 0.33 |
| ▸ | MC5R | P33032 | 3/20 | 0.33 |
| ▸ | MC3R | P41968 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586835 | 0.87 | KMT2A (0.47) | HPGDMAPTALDH1A1GAAACHE | |
| SCHEMBL19392739 | 0.78 | GLA (0.47) | HPGDMAPTALDH1A1GAAKMT2A | |
| SCHEMBL19392680 | 0.77 | TP53 (0.41) | MAPTACHEGLA | |
| SCHEMBL12743956 | 0.76 | PKM (0.46) | — | |
| SCHEMBL1586754 | 0.76 | PKM (0.46) | — | |
| SCHEMBL16348460 | 0.76 | SCNN1A (0.39) | HPGDHTTMAPTALDH1A1GAA | |
| SCHEMBL19392662 | 0.76 | TP53 (0.39) | HTTMAPTALDH1A1ACHEKMT2A | |
| SCHEMBL2126441 | 0.76 | MEN1 (0.40) | HTTMAPTALDH1A1ACHEKMT2A | |
| SCHEMBL12215904 | 0.75 | MAPT (0.39) | HTTMAPTALDH1A1GAAACHE | |
| SCHEMBL19392789 | 0.74 | SOS1 (0.40) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | HPGD 855/4885HTT 2063/4885RECQL 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.